Herzlichen Glückwunsch an Dr. Deni Hardiansyah zum Gewinn des 1. Tomio-Inoue-Preises auf dem 16. Asiatischen und Ozeanischen Kongress für Nuklearmedizin und Biologie (AOCNMB). Die vorgestellte Arbeit beruht auf einer Kooperation der Ulmer Gruppe für Medizinische Strahlenphysik mit der Abteilung für Medizinische Physik und Biophysik der Universitas Indonesia und der Arbeitsgruppe Medizinische Physik in der Klinik für Nuklearmedizin am Uniklinikum Freiburg.
In der Studie mit dem Titel „Single-time-point kidneys and tumor absorbed dose calculation during [177Lu]Lu-PSMA-617 therapy using non-linear mixed-effects modeling“ wurde gezeigt, dass eine einzige SPECT/CT-Messung 2 Tage nach der Injektion die Energiedosen von Nieren und Tumoren bei der [177Lu]Lu-PSMA-617-Therapie gut vorhersagen kann. Der neu entwickelte „STP-NLME“-Ansatz übertrifft die häufig verwendete einfache STP-Methode.
Der Tomio Inoue Award ist eine Auszeichnung, die im Bereich der Nuklearmedizin an Wissenschaftler und Forscher vergeben wird, die einen bedeutenden Beitrag auf diesem Gebiet leisten. Der Preis ist nach Tomio Inoue benannt, einer führenden Persönlichkeit auf dem Gebiet der Nuklearmedizin und Biologie, der für seine wissenschaftlichen Beiträge zur Entwicklung der medizinischen Bildgebungstechnologie und nuklearmedizinischer Therapien anerkannt ist.
The cooperation of the Ulm Group for Medical Radiation Physics with the Department of Medical Physics and Biophysics of Universitas Indonesia was awarded the "International Best Abstract Award for Indonesia" for its contribution to the annual meeting of the Society for Nuclear Medicine and Molecular Imaging (SNMMI).
In molecular radiotherapy, individual determination of time-integrated activities is needed. The aim of this study was to develop an optimised, more reproducible method combining "non-linear mixed-effects" (NLME) modeling with population-based model selection (PBMS) for accurate determination of time-integrated activities. The technique was demonstrated using renal dosimetry in 177Lu-PSMA therapy as an example.
D. Hardiansyah, A. Riana, M. Eiber, A. J. Beer, G. Glatting, " Improving the accuracy of the time-integrated activity using non-linear mixed-effects modeling and population-based model selection in molecular radiotherapy," J Nuc Med 64, P519 (2023).
The cooperation of the Ulm Group for Medical Radiation Physics with the Department of Medical Physics and Biophysics of Universitas Indonesia was awarded the "International Best Abstract Award for Indonesia" for its contribution to the annual meeting of the Society for Nuclear Medicine and Molecular Imaging (SNMMI).
The award-winning contribution explores ways to individualise nuclear medicine therapy using prior knowledge about the patient population.
D. Hardiansyah, A. Riana, P. Kletting, N. Zaid, A. Beer, G. Glatting, "Model Selection Based on Population Fitting at an Example of 177Lu-PSMA Kinetics in Kidneys with a Low Number of Data," J Nuc Med 62, 1435-1435 (2021).
Optimization of prostate cancer diagnostics
Radiological Society of North America Trainee Research Prize for Jonathan Miksch, resident in the Department of Nuclear Medicine.
Jonathan Miksch, a resident in the Department of Nuclear Medicine, is recognized at this year's RSNA (Radiological Society of North America) annual meeting for his submitted paper:
"[F-18]siPSMA-14 PET/CT Acquired at 90 Minutes p.i. Without Forced Diuresis Provides Optimal Contrast for Staging and Restaging of Prostate Cancer Patients" has been awarded the Trainee Research Prize. The prize is endowed with prize money of 1,000 US dollars.
In recent years, the use of radioactive substances with a target structure PSMA (prostate specific membrane antigen) has become established in nuclear imaging of prostate carcinoma. The work of Mr. Miksch presents the promising results of a new radioactive substance and its first clinical application in prostate cancer patients. F-18]siPSMA-14 is a comparatively easy tracer to produce in large quantities and showed optimal conditions for tumor detection 90 minutes after injection, both at initial diagnosis and in the recurrence situation.
The Radiological Society of North America is the world's largest association for radiologists, medical physicists and medical professionals.
Calculating the optimal tumor therapy
Award: Medical physicist Dr. Peter Kletting from Ulm receives the Science Award of the German Society for Medical Physics
The German Society for Medical Physics (DGMP) has awarded Dr. biol. hum. Peter Kletting, medical physicist at the Department of Nuclear Medicine at Ulm University Hospital, with the Science Award 2020 for his research on targeted irradiation of tumor tissue with radioactively labeled peptides.
You can read a detailed description of the research work here.
(Only in german language)
EMIM (ESMI) – Poster Award 2020
The Ulm research group for preclinical imaging, represented by Dr. Gordon Winter, was honored with the "Poster Award" for their contribution at the annual meeting (EMIM) of the European Society for Molecular Imaging (ESMI).
The award-winning work investigates the use of the chicken egg model as an alternative to animal testing with mice in the development of new radiolabeled substances. The results of the studies have already been published.
Nusrat Begum, PhD student in the Department of Nuclear Medicine, was honored with the 2019 Alavi Mandell Award.
Nusrat Jihan Begum, MSc, PhD student in the Department of Nuclear Medicine at Ulm University Hospital has been awarded the American Alavi-Mandell Prize for her publication in The Journal of Nuclear Medicine (JNM, impact factor 7.4 (2017)).
The prize was awarded for her publication entitled
( “The effect of total tumor volume on the biologically effective dose of tumor and kidneys for 177Lu-labelled PSMA peptides”).
Publication by Dr. Peter Kletting, Department of Nuclear Medicine at Ulm University Hospital, was awarded a prize by the German Society of Nuclear Medicine (DGN).
For his achievements in the field of nuclear medicine therapy, Dr. biol. hum. Peter Kletting, a member of staff at the Clinic for Nuclear Medicine | Medical Radiation Physics at Ulm University Hospital, has received this year's sponsorship award from the German Society for Nuclear Medicine (DGN). The award is endowed with 3,000 euros. The prize of the professional society is intended to honor scientific publications that make an outstanding contribution to the establishment or optimization of nuclear medicine therapies. For more information, please see the press release.
(Only in german language)
Dr. biol. hum. Peter Kletting (Ulm) has received one of the 3 Behnken-Berger Prizes 2017 for the development of a method to improve the therapeutic index for radioligand therapy. (Publication)
The award ceremony took place during the joint Annual Meeting of Biomedical Engineering and the Three-Country Meeting of Medical Physics in Dresden on September 11, 2017.
The awarded paper by Dr. Peter Kletting describes a method by the application of which the therapeutic index for radioligand therapy can be improved.
With the help of the physiologically based pharmacokinetic model developed by Dr. Kletting and the simulation algorithm, the combination of activity and amount of peptide used can be determined individually for each patient, leading to the optimal ratio of biologically effective dose in the tumor to organs at risk. As a result, the effectiveness of the therapy is increased while the radiation exposure remains the same, or the radiation exposure to the organs at risk can be minimized for a given effect. The developed method can be transferred to other substances and thus shows an extraordinary relevance for current and future therapy concepts. Therefore, they represent an important step in reducing the radiation exposure of patients. This outstanding work is closely related to the work published by Dr. Kletting so far in the field of therapeutic use with ionizing radiation.
The Ulm and Mannheim Medical Radiation Physics Group were awarded the "International Best Abstract Award" for their contribution to the annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in Denver, Colorado.
The award-winning paper explores ways to individualize nuclear medicine therapy. The results of the research have already been published.
By: Petra Schultze
Ulm medical physicists Dr. Peter Kletting and Prof. Dr. Gerhard Glatting of the University Department of Nuclear Medicine receive the prize for the best scientific article in the Journal of Medical Physics 2015.
Die Kooperation der Ulmer Gruppe für Medizinische Strahlenphysik mit der Abteilung für Medizinische Physik und Biophysik der Universitas Indonesia und der Arbeitsgruppe für Medizinische Physik in der Klinik für Nuklearmedizin am Uniklinikum Würzburg wurde für ihren Beitrag zur Jahrestagung der amerikanischen Gesellschaft für Nuklearmedizin und Molekulare Bildgebung (SNMMI) mit dem "International Best Abstract Award for Indonesia" ausgezeichnet.
Die entwickelte Methode optimiert die Genauigkeit und damit die Reproduzierbarkeit zwischen verschiedenen Untersuchern. Die damit vereinfachte Dosimetrie mit nur einer Messung nach 120 Stunden unter Verwendung der NLME-Methode zeigt, dass diese akzeptabel ist und genaue Werte für die Schilddrüsentherapie mit 131I liefert.
„FIRST PLACE POSTER – Molecular Targeting Probes“.
In dem preisgekrönten Beitrag wird die radiopharmazeutische Produktion eines Alpha-Emitters für den klinischen Einsatz vorgestellt.
Dirk Müller, Christoph Solbach, Mengshi Li, Dijie Liu, Ambros J. Beer, Michael Schultz, Vikas Prasad, "Radiopharmaceutical Production of [Pb-203]VMT-NET for Clinical Use" J Nucl Med 63, Suppl 2 (2022), Poster #2910.
Prof Dr Sven Norbert Reske receives the Georg von Hevesy Medal of the German Society of Nuclear Medicine
The German Society of Nuclear Medicine (DGN) has honoured Prof. Dr Sven Norbert Reske, Medical Director of the University Clinic for Nuclear Medicine in Ulm, with the Georg von Hevesy Medal. The award recognises Reske's achievements in establishing positron emission tomography (PET) in oncology and his contribution to leukaemia research and therapy in the field of radioimmunotherapy.
... [more]
By: Petra Schultze
Patients who have had thyroid cancer have the same risk of the disease recurring after successful treatment, regardless of the original prognosis. This was discovered by a team of nuclear medicine specialists in a long-term study. For their publication, the team of scientists from Würzburg, Ulm, Utrecht (NL), Leiden (NL) and Jersey City (USA) received the Brahms Research Prize for Thyroid Diseases 2010, endowed with 12,750 euros, at this year's annual conference of the German Society of Nuclear Medicine in Leipzig.
The German Society of Nuclear Medicine honours young scientist Peter Kletting from the Department of Nuclear Medicine with the Covidien Nuclear Medicine Award. [more]
Special recognition of the German Radiological Society in the category "Young Investigator Award" at the 90th German Radiological Congress 2009 for Mrs Nina Baier for her contributions:
- Somatostatin analogues in a colon carcinoid mouse model: comparison with FDG and 18F-DOPA
- PET of medullary thyroid carcinoma: Comparison of FDG, 18F-DOPAand 68Ga-DOTA-TOCin a mouse model.
By: Jörg Portius
Medical physicist Prof. Dr Glatting is honoured for his research by the German Society for Medical Physics on 13 September
The German Society for Medical Phys ics (DGMP) is honouring Ulm medical physicist Prof. Dr. Gerhard Glatting for his research into the targeted irradiation of tumour tissue with radioactively labelled antibodies in cancer patients. [more]
A.K. Buck, M. Bommer, M.E. Juweid, G. Glatting, S. Stilgenbauer, F.M. Mottaghy, M. Schulz, T. Kull, D. Bunjes, P. Möller, H. Döhner, S.N. Reske.
First Demonstration of Leukaemia Imaging with the Proliferation Marker 18F-Fluorodeoxythymidine.
J Nucl Med 49: 1756-1762, 2008 (IF=6.662).
Claudia Friesen from the University Clinic for Nuclear Medicine in Ulm received the Dietrich Schmähl Prize, endowed with 6,000 euros, in Freiburg on 16 June. [more]
C. Friesen, G. Glatting, B. Koop, K. Schwarz, A. Morgenstern, C. Apostolidis, K.-M. Debatin, S.N. Reske. Breaking chemo- and radioresistance with[213Bi]anti-CD45 antibodies in leukaemia cells.
Cancer Res 67(5): 1950-1958, 2007.
S.N. Reske, N.M. Blumstein, B. Neumaier, H.-W. Gottfried, F. Finsterbusch, D. Kocot, P. Möller, G. Glatting, S. Perner. Imaging prostate cancer with[11C]Choline PET/CT.
J Nucl Med 47(8): 1249-1254, 2006 (IF=4.684).
Buck AK, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, Glatting G, Mattfeldt T, Neumaier B, Reske SN, Hetzel M: Imaging Proliferation in Lung Tumours with PET -[18F]FLT vs.[18F]FDG.
J Nucl Med 144: 1426-31, 2003.
Reske SN, Kotzerke J. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000. Eur J Nucl Med. 2001 28(11):1707-23.
Buck A, Schirrmeister HH, Guhlmann CA, Diederichs CG, Shen C, Buchmann I, Kotzerke J, Birk D, Mattfeldt T, Reske SN. Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity? J Nucl Med. 2001 May;42(5):721-5.
Schirrmeister H, Kühn T, Guhlmann A, Santjohanser C, Hörster T, Nüssle K, Koretz K, Glatting G, Rieber A, Buck A, Reske SN: [F-18] 2-deoxy-2-fluoro D-glucose PET in preoperative staging of breast cancer - comparison with the standard imaging procedures.
Eur J Nucl Med 28: 351-358, 2001.
Helax Prize 1998 for the best lecture "Computer Applications in Medical Physics" on the topic: "Non-invasive calculation of cerebral blood flow from O-15 water PET data" by Dr Gerhard Glatting
Editor's Excellence Awards for Outstanding Scientific Research 1996 of the "Journal of Computer Assisted Tomography" for the article
C.G. Diederichs, D.P. Keating, G. Glatting, J.W. Oestmann. Blurring of Vessels in Spiral CT Angiography: Effects of Collimation Width, Pitch, Viewing Plane, and Windowing in Maximum Intensity Projection. J Comput Assist Tomogr 20(6): 965-974, 1996.